Real life evaluation of safinamide effectiveness in Parkinson’s disease

Francesca Mancini, Alessio Di Fonzo, Giulia Lazzeri, Linda Borellini, Vincenzo Silani, Marco Lacerenza, Cristoforo Comi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson’s disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson’s Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.

Original languageEnglish
Pages (from-to)733-739
Number of pages7
JournalNeurological Sciences
Volume39
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Parkinson Disease
Dyskinesias
Levodopa
Guaiacol
safinamide
Monoamine Oxidase Inhibitors
Dopamine Agonists
Monoamine Oxidase
Transferases
Pharmaceutical Preparations
Walking
Retrospective Studies

Keywords

  • Dyskinesias
  • Motor fluctuations
  • Parkinson’s disease
  • Safinamide

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Real life evaluation of safinamide effectiveness in Parkinson’s disease. / Mancini, Francesca; Di Fonzo, Alessio; Lazzeri, Giulia; Borellini, Linda; Silani, Vincenzo; Lacerenza, Marco; Comi, Cristoforo.

In: Neurological Sciences, Vol. 39, No. 4, 2018, p. 733-739.

Research output: Contribution to journalArticle

Mancini, Francesca ; Di Fonzo, Alessio ; Lazzeri, Giulia ; Borellini, Linda ; Silani, Vincenzo ; Lacerenza, Marco ; Comi, Cristoforo. / Real life evaluation of safinamide effectiveness in Parkinson’s disease. In: Neurological Sciences. 2018 ; Vol. 39, No. 4. pp. 733-739.
@article{4ca0d30927e249df98f34da55ac422a2,
title = "Real life evaluation of safinamide effectiveness in Parkinson’s disease",
abstract = "In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson’s disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson’s Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.",
keywords = "Dyskinesias, Motor fluctuations, Parkinson’s disease, Safinamide",
author = "Francesca Mancini and {Di Fonzo}, Alessio and Giulia Lazzeri and Linda Borellini and Vincenzo Silani and Marco Lacerenza and Cristoforo Comi",
year = "2018",
doi = "10.1007/s10072-018-3272-y",
language = "English",
volume = "39",
pages = "733--739",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "4",

}

TY - JOUR

T1 - Real life evaluation of safinamide effectiveness in Parkinson’s disease

AU - Mancini, Francesca

AU - Di Fonzo, Alessio

AU - Lazzeri, Giulia

AU - Borellini, Linda

AU - Silani, Vincenzo

AU - Lacerenza, Marco

AU - Comi, Cristoforo

PY - 2018

Y1 - 2018

N2 - In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson’s disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson’s Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.

AB - In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson’s disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson’s Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.

KW - Dyskinesias

KW - Motor fluctuations

KW - Parkinson’s disease

KW - Safinamide

UR - http://www.scopus.com/inward/record.url?scp=85041910335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041910335&partnerID=8YFLogxK

U2 - 10.1007/s10072-018-3272-y

DO - 10.1007/s10072-018-3272-y

M3 - Article

VL - 39

SP - 733

EP - 739

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 4

ER -